RxDoctor Payments Data

Raymond Miller, NP

Nurse Practitioner · Ogden, UTNPI 1518401397

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 92.3% of the total across 363 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 17.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,573, 2.1 times the $744 reported in 2021. Among nurse practitioner clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,383in general payments, 2019–2025

Across 363 payments — averaging $17.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$1K
  • Sumitomo Pharma America, Inc.$666
  • 180 Medical, Inc.$609
  • AbbVie$574
  • Dendreon Pharmaceuticals LLC$529
  • Pfizer$328
  • plus $3K from 33 others

What the payments were for

  • Food & beverage$5,88992%
  • Education$4948%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,383 in reported general payments places this provider in the 95th percentile of 979 nurse practitioner providers in Utah.

See all nurse practitioner providers in Utah

Medicare billing

Part B allowed, 2024
$180,007
Medicare patients
719
Services billed
6,783

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron314$216,804
OrgovyxRelugolix11$28,675
Tamsulosin Hcl801$11,434
Methenamine Hippurate81$8,805
Mirabegron ErMirabegron11$7,732
Cephalexin346$7,408
Potassium Citrate ErPotassium Citrate33$7,369
Trospium Chloride99$7,224
Estradiol75$5,121
Finasteride433$4,329
Fosfomycin Tromethamine16$4,062
Solifenacin Succinate45$1,491
CefuroximeCefuroxime Axetil42$1,326
Testosterone Cypionate50$1,272
Ciprofloxacin Hcl138$1,259

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$1,089$216,804314 claims
Sumitomo Pharma America, Inc.Orgovyx$666$28,67511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 979 nurse practitioner providers in Utah.

Other nurse practitioner in Ogden

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →